Ardelyx: Demand for IBSRELA and XPHOZAH Leads to a Surprise - Experts see up to 140% Price Potential

Ardelyx (ARDX) reported its Q2 earnings after the market closed on August 4. The biotech's total revenue amounted to $97.7 million, representing an impressive growth of 33% compared to the previous year. Ardelyx recorded net sales of $65.0 million for IBSRELA, while XPHOZAH contributed net sales of $25.0 million. Mike Raab, president and CEO of Ardelyx, emphasized that both commercial products have delivered significant results, highlighting their important role for patients. The EPS was reported at -$0.08, compared to -$0.07 in the same period...